Monthly research recap
Microdosing research: September 2026
What September 2026's 7 new studies found, synthesized from the papers below. All Microdosing research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.
Research on microdosing in September 2026 is dominated by non-psychedelic agricultural and pharmacological work, with the most directly relevant clinical evidence being a randomized controlled trial of LSD microdosing for major depressive disorder that found no benefit over an active placebo (caffeine). Two theoretical papers on psilocybin microdosing argue that dosing schedule may be a distinct pharmacological variable and propose testable receptor-adaptation hypotheses, but neither provides efficacy evidence. Overall, the clinical evidence does not support microdosing as an effective treatment for depression, and the psychedelic findings remain hypothesis-generating rather than confirmatory.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| 230. LSD microdosing for depression: hype or hope? A randomised controlled trial in major depressive disorder 2026 | RCT | Opposes | Microdosed LSD was not superior to active placebo (caffeine) for reducing depressive symptoms, with MADRS scores falling 29.9% on LSD versus 36.4% on placebo, a non-significant difference with moderate evidence favoring the null. | |
| Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure 2026 | theoretical | Unclear | Argues that dosing schedule should be treated as an independent pharmacological variable in psilocybin microdosing research, noting that the first dedicated randomized trial in major depressive disorder (2 mg psilocybin once weekly) did not demonstrate superiority over placebo and that continuous daily exposure remains inadequately tested. | |
| Daily Psilocybin Microdosing as a Receptor-Adaptation Paradigm: A Testable 5-HT2A Down-Regulation Hypothesis 2026 | theoretical | Unclear | Proposes that daily low-dose psilocybin may induce progressive 5-HT2A receptor desensitization, with fading subjective effects marking an adaptive state rather than therapeutic failure, and that intermittent schedules may test a different chronic pharmacology; the hypothesis is not evidence of efficacy. | |
| Considerations and challenges in microdosing of GLP-1-based receptor agonists. 2026 | commentary | Unclear | Argues that microdosing GLP-1-based therapies (25-50% of recommended starting doses or extended dosing intervals) has gained traction off-label during shortages, with early reports suggesting reduced nausea, improved adherence, and modest weight loss, but that high-quality clinical evidence is essentially absent and safety concerns persist. | |
| Integrated Microdosing Selected Basal Fertilizers and Lime Modulates Fungal and Bacterial Populations in Acidic Soils under Maize Production in the Meru Highland, Kenya 2026 | field experiment | Supports | Microdosing (75% of recommended fertilizer and lime rates) combined with calcite + NPK 23:23:0 + farmyard manure produced the highest culturable fungal and bacterial populations, significantly exceeding the same treatment at full rates and untreated controls. | |
| Enhancing maize ( Zea Mays L.) resilience to climate change: The role of supplemental irrigation and fertiliser microdosing in improving grain‐filling rates of drought‐tolerant varieties in northern Benin 2026 | field experiment | Supports | Supplemental irrigation raised the maize grain-filling rate from 70 to 90 g/day, and drought-tolerant varieties filled grain at 90-110 g/day versus 70 g/day for a drought-sensitive variety; the authors argue breeding programmes should incorporate resource-efficient practices like supplemental irrigation and fertiliser microdosing. | |
| Evaluation of different mineral fertilizer microdosing options to optimize the productivity of Pearl millet hybrids (Pennisetum glaucum (L.) R. Br.) in the central groundnut basin of Senegal 2026 | field trial | Supports | Microdose mineral fertiliser treatments gave grain and dry biomass yields statistically equivalent to the standard full-dose treatment while showing the best agronomic efficiencies. |
Points of agreement
- The two psilocybin theoretical papers agree that dosing schedule is an under-tested variable and that intermittent schedules may not capture the pharmacology of continuous exposure.
- The agricultural field studies converge in finding that microdosing (reduced fertilizer rates) can match or improve outcomes relative to full-dose or untreated controls.
- The LSD RCT and the psilocybin theoretical papers together indicate that clinical efficacy of psychedelic microdosing is not established.
Conflicts
- The LSD RCT found no benefit over active placebo for depression, whereas community and naturalistic reports cited in the theoretical papers suggest subjective promise; the theoretical papers explicitly note that the dedicated psilocybin trial did not show superiority over placebo.
- Agricultural microdosing studies report positive yield or microbial benefits, which is a different domain from clinical psychedelic microdosing and cannot be generalized to it.
Gaps
- No controlled clinical trial of psilocybin microdosing for depression is reported here; the only dedicated trial cited did not show superiority over placebo.
- Durability of any microdosing effect is unaddressed.
- Blinding integrity and expectancy effects are not resolved in the clinical evidence.
- Continuous versus intermittent dosing schedules and receptor-adaptation states remain untested in humans.
- Long-term safety, including possible 5-HT2B-mediated valvular effects, is unresolved.
- Dose-response relationships for psychedelic microdosing are not established.